World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Harris, Nancy L.; Jaffe, Elaine S.; Diébold, J; Flandrin, Georges; Müller‐Hermelink, Hans Konrad; Vardiman, James W.; Lister, T. A.; Bloomfield, Clara D.

doi:10.1200/jco.1999.17.12.3835

Cited by 2,671 publications

(1,492 citation statements)

References 3 publications

Supporting

Mentioning

1,393

Contrasting

Unclassified

Order By: Relevance

“…All tumor samples underwent histological review by members of the reference pathologist panel of the Deutsche Krebshilfe network. Diagnoses of B-cell lymphoma were established according to World Health Organization (WHO) criteria (Harris et al, 1999). In the two patients with REL mutations, the diagnoses of FL and mediastinal lymphoma were confirmed.…”

Section: Methodsmentioning

confidence: 99%

Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity

et al. 2006

View full text Add to dashboard Cite

The human c-rel proto-oncogene (REL) encodes a subunit of the nuclear factor-kappaB (NF-jB) transcription factor. In this report, we have identified an identical point mutation in two human B-cell lymphomas (follicular (FL) and mediastinal) that changes serine (Ser)525 (TCA) to proline (Pro) (CCA) within the REL transactivation domain. This mutation was not identified in a similarly sized cohort of healthy individuals. In the mediastinal B-cell lymphoma, the mutation in REL is of germ-line origin. In both tumors, the S525P mutant allele is overrepresented. REL-S525P shows enhanced in vitro transforming activity in chicken spleen cells. REL-S525P has a reduced ability to activate the human manganese superoxide dismutase (MnSOD) promoter in A293 cells; however, the MnSOD protein shows increased expression in REL-S525P-transformed chicken spleen cells as compared to wild-type REL-transformed cells. Ser525 is a site for phosphorylation by IjB kinase (IKK) in vitro. The S525P mutation reduces IKKa-and tumor necrosis factor (TNF)a-stimulated transactivation by a GAL4-REL protein. Furthermore, REL-S525P-transformed chicken spleen cells are more resistant to TNFa-induced cell death than cells transformed by wild-type REL. These results suggest that the S525P mutation contributes to the development of human B-cell lymphomas by affecting an IKKa-regulated transactivation activity of REL.

show abstract

Section: Methodsmentioning

confidence: 99%

Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity

et al. 2006

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] Although the clinical behavior of primary cutaneous BCL is dramatically different from those diagnosed in lymph nodes, 1,2,5,7-9 the morphology is strikingly similar. Until now no clear immunophenotypical or molecular differences have been known, [10][11][12] except that t(14;18) occurs rarely in skin follicular lymphomas (FLs), while it is characteristic of nodal FLs.…”

mentioning

confidence: 99%

“…10,[13][14][15] At the same time, it seems that primary cutaneous BCL constitutes a heterogeneous group encompassing tumors denominated as FL, marginal-zone BCL and diffuse large BCL, although the precise distinction of these different cutaneous BCLs is a matter of controversy. 1,2,5,7,[16][17][18] Underlying all the uncertainties about the knowledge and classification of cutaneous BCLs is the relative paucity of available information about distinctive molecular events, with the exception of the identification of local phenomena such as Borrelia burgdorferi infection, and the expression of skin-related adhesion molecules [19][20][21] in a subset of cutaneous BCLs.…”

mentioning

confidence: 99%

IgV and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens

et al. 2004

View full text Add to dashboard Cite

Our understanding of the ontology of B-cell lymphomas (BCL) has been improved by the study of mutational status of IgV H and bcl6 genes, but only a few cases of cutaneous BCL have been examined for this status. We analyzed IgV H and bcl6 somatic mutations in 10 cutaneous BCL, classified as follicular (three primary and one secondary), primary marginal zone (two cases), and diffuse large BCL (three primary and one secondary). We observed a lower rate (o2%) of IgV H mutation in all marginal zone lymphomas, and a preferential usage of V H 2-70 (one primary follicular and two primary diffuse large BCL). Fewer than expected replacement mutations in framework regions (FR) were observed in three primary follicular lymphomas (FLs) and in all diffuse large BCL, indicating a negative antigen selection pressure. Ongoing mutations were observed in eight of 10 cases. Only two primary FLs and two diffuse large BCL showed bcl6 somatic mutation. These data support the heterogeneous nature of the different cutaneous BCL, and specifically the distinction between cutaneous follicular and marginal zone lymphomas. The biased usage of V H 2-70, the low rate of replacement mutation in the FR, and the presence of ongoing mutation imply that local antigens could modulate the growth of primary cutaneous BCL.

show abstract

“…Since the advent of REAL/WHO classification, PMBCL is defined as a distinct clinicopathological entity [1]. Its peculiar morphologic and molecular genetic profile, as well as the aggressive clinical evolution, has been widely described [2,3].…”

Section: Discussionmentioning

confidence: 99%

“…Primary mediastinal B-cell lymphoma (PMBCL) is a distinct, diffuse, large B-cell lymphoma (DLCL) in the REAL/WHO classification [1], showing peculiar histological, phenotypical, and clinical characteristics.…”

Section: Introductionmentioning

confidence: 99%

Primary mediastinal B‐cell lymphoma with sclerosis: Report of 11 cases treated with intensified‐CHOP plus radiotherapy

et al. 2005

View full text Add to dashboard Cite

Primary mediastinal B-cell lymphoma (PMBCL) is a clinicopathological entity with aggressive behavior. Retrospective evaluation suggests the need for intensive chemotherapy programs. From 1997 to February 2003, a total of 11 cases of previously untreated PMBCL with sclerosis were treated at our institution with 5 courses of intensified CHOP (ICHOP) regimen and mediastinal irradiation. Three patients were submitted to high-dose chemotherapy with peripheral-blood stem-cell support, followed by radiotherapy, because of intermediate-risk age-adjusted International Prognostic Index at diagnosis. After a median follow up of 30 months, all patients but one are in continuous complete remission (CR), and overall survival is 100%. Am.

show abstract

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Abstract: The WHO classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies.

Cited by 2,671 publications

References 3 publications

Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity

Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity

IgV and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens

Primary mediastinal B‐cell lymphoma with sclerosis: Report of 11 cases treated with intensified‐CHOP plus radiotherapy

Contact Info

Product

Resources

About